Bioavailability is the fraction of an administered drug or active substance that reaches the systemic circulation in an unchanged form, together with the rate at which this occurs. In translation and localization, it appears in pharmacokinetic studies, product information, regulatory submissions, and labeling where absorption characteristics, absolute versus relative bioavailability, and factors affecting exposure are described.
Bioavailability appears in pharmacokinetic study reports, clinical study protocols, summaries of product characteristics, and regulatory dossiers. Translators handle phrases such as absolute bioavailability, relative bioavailability, AUC, and Cmax, often in tables and statements comparing formulations, routes of administration, and the effect of food.
A common mistake is confusing bioavailability with bioequivalence or simple absorption. Bioavailability describes the fraction and rate at which a drug reaches the systemic circulation for a given product; bioequivalence compares two products. Interchanging these terms can change study conclusions, misstate labeling claims, and trigger regulatory queries.
FDA, CE/MDR and NMPA reviewers assess the submitted wording itself. Regulatory bodies require traceable, accountable translation, and an inconsistent term can delay or fail a submission.
Angel Translation locks terms like this into a project terminology base before expert review begins, so the same source term resolves to the same target term across every document in a submission — and stays consistent in the next revision. See the 8-step AI + expert workflow.
Send us the files. Acknowledged in 4 hours, quoted in 24.
Request a Quote →Life Science solutions →